In the latest quarter, 6 analysts provided ratings for Xylem XYL, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $141.17, with a high estimate of $150.00 and a low estimate of $126.00. Observing a 8.43% increase, the current average has risen from the previous average price target of $130.20.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Xylem among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Buscaglia | Exane BNP Paribas | Announces | Outperform | $150.00 | - |
| Nathan Jones | Stifel | Raises | Buy | $150.00 | $136.00 |
| Andrew Kaplowitz | Citigroup | Raises | Neutral | $126.00 | $122.00 |
| Deane Dray | RBC Capital | Raises | Outperform | $145.00 | $140.00 |
| Deane Dray | RBC Capital | Raises | Outperform | $140.00 | $120.00 |
| Nathan Jones | Stifel | Raises | Buy | $136.00 | $133.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xylem compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Xylem's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Xylem analyst ratings.
Delving into Xylem's Background
Xylem Inc is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $7.4 billion in revenue in 2023.
Financial Insights: Xylem
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Xylem's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.64% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Xylem's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Xylem's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.65%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Xylem's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.24, Xylem adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
